Active Biotech presents data on paquinimod at EULAR 2014
June 11 2014 - 2:30AM
Lund, Sweden, June 11, 2014,
Active Biotech (NASDAQ OMX NORDIC: ACTI) will present data
related to the drug candidate paquinimod (57-57) for the treatment
of systemic sclerosis, at the scientific conference "EULAR Annual
European Congress of Rheumatology" held in Paris on June 11-14,
2014.
Active Biotech presentations include:
- (FRI0496) An open-label study to evaluate
biomarkers and safety in systemic sclerosis (SSc) patients treated
with paquinimod (ABR-215757). Hesselstrand R., Distler J.H.,
Riemekasten G., Törngren M., Nyhlén H. C., Stenström M., Andersson
F., Eriksson H., Sparre B., Tuvesson H., Distler O. In
this study, nine patients were treated with paquinimod 3 mg/day for
eight weeks. The primary endpoint of the study was changes in
disease related biomarkers. Paquinimod was well tolerated and
effects on biomarkers relevant for SSc were observed during
treatment.
- (FRI0516) Paquinimod
(ABR-215757), an immunomodulatory compound, reduces fibrosis in the
tight-skin 1 (TSK-1) model for systemic sclerosis. Stenström M.,
Nyhlén H. C., Nilsson M., Eriksson H., Törngren M., Distler J.H.,
Distler O., Sparre B., Tuvesson H. The purpose of this
pre-clinical study was to investigate the effects of paquinimod in
an experimental disease model for systemic sclerosis. The results
show that paquinimod reduces development of skin fibrosis in this
disease model.
For more detailed information, please see
www.eular.org.
About
paquinimod
Paquinimod is a quinoline compound primarily intended for the
treatment of systemic sclerosis. This rare disease is classified as
an orphan drug indication. In 2011 and 2014, paquinimod was granted
orphan medicinal product status in Europe and US for the indication
systemic sclerosis. The Orphan Medicinal Product Designation is
implemented to promote the development of drugs that may provide
significant benefit to patients suffering from rare diseases
identified as life-threatening or chronically debilitating.
About Active
Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology
company with focus on autoimmune/inflammatory diseases and cancer.
In pivotal phase is laquinimod (NERVENTRA®), an orally administered
small molecule with unique immunomodulatory properties for the
treatment of multiple sclerosis. Also tasquinimod for the treatment
of prostate cancer, with a unique mode of action, is in pivotal
phase. In addition, laquinimod has concluded Phase II development
for Crohn's and Lupus. The company has two additional projects in
clinical development, ANYARA primarily for the treatment of renal
cell cancer and the orally administered compound paquinimod (57-57)
for systemic sclerosis. Please visit www.activebiotech.com for more
information.
For further information,
please contact:
Tomas Leanderson, President & CEO
Tel: +46 (0)46 19 20 95
Email: tomas.leanderson@activebiotech.com
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
E-mail: hans.kolam@activebiotech.com
Active Biotech AB (Corp. Reg. No.
556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is required under
the Financial Instruments Trading Act to make the information in
this press release public. The information was submitted for
publication at 08:30 a.m. CET on June 11, 2014.
Active Biotech presents data on
paquinimod at EULAR 2014
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
HUG#1791728
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024